These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 19815494

  • 1. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.
    Van den Bosch F, Manger B, Goupille P, McHugh N, Rødevand E, Holck P, van Vollenhoven RF, Leirisalo-Repo M, Fitzgerald O, Kron M, Frank M, Kary S, Kupper H.
    Ann Rheum Dis; 2010 Feb; 69(2):394-9. PubMed ID: 19815494
    [Abstract] [Full Text] [Related]

  • 2. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study.
    Gladman DD, ACCLAIM Study Investigators, Sampalis JS, Illouz O, Guérette B.
    J Rheumatol; 2010 Sep; 37(9):1898-906. PubMed ID: 20595284
    [Abstract] [Full Text] [Related]

  • 3. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, Perdok RJ, Sasso EH.
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [Abstract] [Full Text] [Related]

  • 4. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
    Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, Tahir H, Gooderham M, Krishnan E, Liu-Seifert H, Emery P, Pillai SG, Helliwell PS, SPIRIT H2H study group.
    Ann Rheum Dis; 2020 Jan; 79(1):123-131. PubMed ID: 31563894
    [Abstract] [Full Text] [Related]

  • 5. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J.
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
    Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, Medich J, Sasso EH, M02-570 Study Group.
    J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
    Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H.
    Arthritis Res Ther; 2010 May; 12(3):R117. PubMed ID: 20553600
    [Abstract] [Full Text] [Related]

  • 8. Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors.
    Kirkham B, Sesin C, Gellett AM, Sprabery AT, Lin CY, Turkiewicz A.
    Rheumatology (Oxford); 2021 Sep 01; 60(9):4367-4372. PubMed ID: 33479721
    [Abstract] [Full Text] [Related]

  • 9. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).
    Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, Birbara C, Thomson GT, Perdok RJ, Medich J, Wong RL, Gladman DD.
    Ann Rheum Dis; 2009 May 01; 68(5):702-9. PubMed ID: 18684743
    [Abstract] [Full Text] [Related]

  • 10. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.
    Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J.
    Ann Rheum Dis; 2007 Feb 01; 66(2):163-8. PubMed ID: 17046964
    [Abstract] [Full Text] [Related]

  • 11. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT.
    Mease PJ, Heckaman M, Kary S, Kupper H.
    J Rheumatol; 2013 May 01; 40(5):647-52. PubMed ID: 23504383
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
    Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, Oezer U, Kary S, Kupper H, Burmester GR, Research in Active Rheumatoid Arthritis (ReAct) Study Group.
    Rheumatology (Oxford); 2007 Jul 01; 46(7):1191-9. PubMed ID: 17504821
    [Abstract] [Full Text] [Related]

  • 13. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.
    Karanikolas GN, Koukli EM, Katsalira A, Arida A, Petrou D, Komninou E, Fragiadaki K, Zacharioudaki A, Lasithiotakis I, Giavri E, Vaiopoulos G, Sfikakis PP.
    J Rheumatol; 2011 Nov 01; 38(11):2466-74. PubMed ID: 21885499
    [Abstract] [Full Text] [Related]

  • 14. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.
    Paul C, van de Kerkhof P, Puig L, Unnebrink K, Goldblum O, Thaçi D.
    Eur J Dermatol; 2012 Nov 01; 22(6):762-9. PubMed ID: 23178916
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of adalimumab in Japanese patients with psoriatic arthritis and inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs): A prospective, observational study.
    Morita A, Okuyama R, Katoh N, Tateishi C, Masuda K, Komori T, Ogawa E, Makino T, Nishida E, Nishimoto S, Muramoto K, Tsuruta D, Ihn H.
    Mod Rheumatol; 2020 Jan 01; 30(1):155-165. PubMed ID: 30836036
    [Abstract] [Full Text] [Related]

  • 16. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
    Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A.
    Arthritis Rheum; 2009 Apr 01; 60(4):976-86. PubMed ID: 19333944
    [Abstract] [Full Text] [Related]

  • 17. Long-term treatment of psoriatic patients with adalimumab reduces disease severity and maintains a favorable lipid pattern and a low Atherogenic Index.
    Zangrilli A, Bavetta M, Scaramella M, Bianchi L.
    G Ital Dermatol Venereol; 2018 Apr 01; 153(2):146-154. PubMed ID: 29564871
    [Abstract] [Full Text] [Related]

  • 18. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.
    Atteno M, Peluso R, Costa L, Padula S, Iervolino S, Caso F, Sanduzzi A, Lubrano E, Del Puente A, Scarpa R.
    Clin Rheumatol; 2010 Apr 01; 29(4):399-403. PubMed ID: 20066450
    [Abstract] [Full Text] [Related]

  • 19. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status.
    van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, Beckmann C, Unnebrink K, Kupper H.
    Clin Rheumatol; 2008 Aug 01; 27(8):1021-8. PubMed ID: 18350329
    [Abstract] [Full Text] [Related]

  • 20. Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations.
    Van den Bosch F, Kavanaugh A, Kron M, Kupper H, Mease PJ.
    J Rheumatol; 2015 Jun 01; 42(6):952-9. PubMed ID: 25834212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.